Skip to content

Effect of peanut in appetite and diabetes risk

Acute and second meal effects of peanuts on glycemic response and appetite in obese women a randomized crossover trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
REBEC
Registry ID
RBR-3d9kqb
Enrollment
Unknown
Registered
2011-06-29
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impaired glucose tolerance, Type 2 diabetes mellitus, Obesity

Interventions

Fifteen obese women with high type 2 diabetes risk participated in a randomized crossover trial lasting 8 hours where 42.5g of whole peanuts (P), peanut butter (PB), or no peanuts (control - C) were a
other
B01.650.940.800.575.100.401.077

Sponsors

Universidade Federal de Viçosa
Lead Sponsor
Peanut Collaborative Research Support Program
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 18 - 60 years, body mass index between 30 - 35 kg/m2, not taking medications known to affect glycemia, fat metabolism, or appetite; regular breakfast consumer (?100 kilocalories ingested within 2 hours of waking on ?4d/wk); no body weight fluctuation (<5kg in the past 3 months); willingness to eat all test foods; no self-reported allergy to the foods provided in the study; no self-reported sleep disorders; at least one of the following conditions: waist circumference ? 88 cm; reported family history of type 2 diabetes in first degree relatives; capillary glycemia between 5.5 – 7.0 mmol/L; and/or a 2-hour blood glucose of 7.8 – 11.1 mmol/L (impaired glucose tolerance).

Exclusion criteria

Exclusion criteria: Type 2 diabetes, dyslipidemia or high blood pressure.

Design outcomes

Primary

MeasureTime frame
Improvement on glucose homeostasis (Glucose, insulin and free fatty acids)

Secondary

MeasureTime frame
Higher concentration of Glucagon-like peptide-1 , cholecystokinin and Peptide YY; Increase satiety; Reduction of food intake.

Countries

Brazil

Contacts

Public ContactRita ;Caio Alfenas;Reis

Universidade Federal de Viçosa;Universidade de Brasília

ralafenas@ufv.br;caioedureis@gmail.com+55 31 38993740;+55 61 33072193

Outcome results

None listed

Source: REBEC (via WHO ICTRP)